622 related articles for article (PubMed ID: 7686469)
1. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Plosker GL; Faulds D
Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
[TBL] [Abstract][Full Text] [Related]
2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
3. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.
Coukell AJ; Faulds D
Drugs; 1997 Mar; 53(3):453-82. PubMed ID: 9074845
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
Ormrod D; Holm K; Goa K; Spencer C
Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
[TBL] [Abstract][Full Text] [Related]
5. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
Kaklamani VG; Gradishar WJ
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
[TBL] [Abstract][Full Text] [Related]
6. Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J
Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
Khasraw M; Bell R; Dang C
Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
[TBL] [Abstract][Full Text] [Related]
8. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
Cersosimo RJ; Hong WK
J Clin Oncol; 1986 Mar; 4(3):425-39. PubMed ID: 3005521
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
Spencer CM; Faulds D
Drugs; 1994 Nov; 48(5):794-847. PubMed ID: 7530632
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
Findlay BP; Walker-Dilks C
Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin as adjuvant therapy in breast cancer.
Earl H; Iddawela M
Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
Conte P; Gennari A; Guarneri V; Landucci E; Donati S; Salvadori B; Bengala C; Orlandini C; Baldini E
Oncology (Williston Park); 2001 May; 15(5 Suppl 7):21-3. PubMed ID: 11396360
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin in combination with the taxanes.
Trudeau M; Pagani O
Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
Danesi R; Conte PF; Del Tacca M
Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
[TBL] [Abstract][Full Text] [Related]
17. Anthracyclines in the treatment of gynecologic malignancies.
Maluf FC; Spriggs D
Gynecol Oncol; 2002 Apr; 85(1):18-31. PubMed ID: 11925115
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
[TBL] [Abstract][Full Text] [Related]
20. Current status of epirubicin (Farmorubicin) in the treatment of solid tumours.
Mouridsen HT; Alfthan C; Bastholt L; Bergh J; Dalmark M; Eksborg S; Hellsten S; Kjaer M; Peterson C; Skovsgård T
Acta Oncol; 1990; 29(3):257-85. PubMed ID: 2194531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]